NZ751972A - Treatment of prurigo nodularis - Google Patents

Treatment of prurigo nodularis

Info

Publication number
NZ751972A
NZ751972A NZ751972A NZ75197217A NZ751972A NZ 751972 A NZ751972 A NZ 751972A NZ 751972 A NZ751972 A NZ 751972A NZ 75197217 A NZ75197217 A NZ 75197217A NZ 751972 A NZ751972 A NZ 751972A
Authority
NZ
New Zealand
Prior art keywords
day
treating
pruritus agent
prurigo nodularis
pruritus
Prior art date
Application number
NZ751972A
Other languages
English (en)
Inventor
Thomas Sciascia
Jennifer Good
Amale Hawi
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of NZ751972A publication Critical patent/NZ751972A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ751972A 2016-10-25 2017-10-25 Treatment of prurigo nodularis NZ751972A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662412578P 2016-10-25 2016-10-25
PCT/US2017/058294 WO2018081273A1 (en) 2016-10-25 2017-10-25 Treatment of prurigo nodularis

Publications (1)

Publication Number Publication Date
NZ751972A true NZ751972A (en) 2022-12-23

Family

ID=62025443

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ751972A NZ751972A (en) 2016-10-25 2017-10-25 Treatment of prurigo nodularis

Country Status (11)

Country Link
US (3) US20180125840A1 (https=)
EP (1) EP3532061A4 (https=)
JP (2) JP2019532112A (https=)
KR (1) KR102696347B1 (https=)
CN (1) CN109862895A (https=)
AU (1) AU2017350852A1 (https=)
BR (1) BR112019008241A2 (https=)
CA (1) CA3038544A1 (https=)
MX (1) MX2019004804A (https=)
NZ (1) NZ751972A (https=)
WO (1) WO2018081273A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112672743A (zh) * 2018-07-11 2021-04-16 特雷维治疗股份有限公司 肝病瘙痒症状的治疗
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
IL294601A (en) * 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
US12508259B2 (en) 2022-02-01 2025-12-30 HUMANWELL PHARMACEUTICAL US, Inc. Pharmaceutical formulations containing Nalbuphine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537298A (ja) * 2002-08-02 2005-12-08 ペンウェスト ファーマシューティカルズ カンパニー メトホルミンの徐放性製剤
JP2005162736A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
AU2004299077A1 (en) * 2003-12-12 2005-06-30 Penwest Pharmaceuticals Co. Sustained release torsemide dosage forms
EP1931315B1 (en) * 2005-08-24 2013-10-16 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
WO2009097463A1 (en) * 2008-01-29 2009-08-06 Superdimension, Ltd. Target identification tool for intra body localization
KR20220044385A (ko) * 2012-12-14 2022-04-07 트레비 테라퓨틱스, 인코포레이티드 소양증을 치료하는 방법
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2015192071A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
US20170216277A1 (en) * 2016-01-06 2017-08-03 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用

Also Published As

Publication number Publication date
JP2019532112A (ja) 2019-11-07
JP2022191405A (ja) 2022-12-27
EP3532061A1 (en) 2019-09-04
US20230338367A1 (en) 2023-10-26
KR20190073385A (ko) 2019-06-26
WO2018081273A1 (en) 2018-05-03
CN109862895A (zh) 2019-06-07
US20180125840A1 (en) 2018-05-10
US20220347171A1 (en) 2022-11-03
MX2019004804A (es) 2019-08-22
CA3038544A1 (en) 2018-05-03
BR112019008241A2 (pt) 2019-07-16
KR102696347B1 (ko) 2024-08-19
AU2017350852A1 (en) 2019-04-11
EP3532061A4 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
MX2021002321A (es) Nuevos metodos.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NZ714963A (en) Compositions and methods for treating anemia
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
AU2012284627A8 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
RU2017134443A (ru) Способ лечения с применением традипитанта
ZA202000028B (en) Use of vibegron to treat overactive bladder
NZ751972A (en) Treatment of prurigo nodularis
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
JP2016505050A5 (https=)
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
MX2022012693A (es) Composicion que comprende metilfolato.
EP4461362A3 (en) Nk1-antagonist combination and method for treating synucleinopathies
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
MX381515B (es) Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2024 BY COMPUTER PACKAGES INC

Effective date: 20230930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2025 BY COMPUTER PACKAGES INC

Effective date: 20240930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2026 BY COMPUTER PACKAGES INC

Effective date: 20250930